Back
Full-text
Journal article

Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics.

  • Brough HA Department of Women and Children's Health, Children's Allergy Service, Evelina Children's Hospital, Guy's and St. Thomas' Hospital NHS Foundation Trust, Paediatric Allergy Group, School of Life Course Sciences, King's College London, London, UK.
  • Kalayci O Hacettepe University School of Medicine, Ankara, Turkey.
  • Sediva A Department of Immunology, 2nd Medical Faculty, Charles University and Motol University Hospital, Prague, Czech Republic.
  • Untersmayr E Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
  • Munblit D Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
  • Rodriguez Del Rio P Allergy Department, Hospital Infantil Universitario Niño Jesus, Madrid, Spain.
  • Vazquez-Ortiz M Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, UK.
  • Arasi S Pediatric Allergology Unit, Department of Pediatric Medicine, Bambino Gesù Children's research Hospital (IRCCS), Rome, Italy.
  • Alvaro-Lozano M Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Spain.
  • Tsabouri S Child Health Department, University of Ioannina School of Medicine, Ioannina, Greece.
  • Galli E Pediatric Allergology Unit, Department of Pediatric Medicine, S.Pietro Hospital Fatebenefratelli, Rome, Italy.
  • Beken B Department of Pediatric Allergy and Immunology, Istanbul Health Sciences University Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey.
  • Eigenmann PA Pediatric Allergy Unit, Department of Woman, Child and Adolescent, University Hospitals of Geneva, Geneva, Switzerland.
Show more…
  • 2020-04-23
Published in:
  • Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. - 2020
COVID-19
SARS-CoV-2
allergy
asthma
biologics
children
coronavirus
corticosteroids
immunodeficiency
treatment
Academies and Institutes
Adolescent
Betacoronavirus
Child
Child, Preschool
Coronavirus Infections
Europe
Humans
Hypersensitivity
Immunologic Deficiency Syndromes
Infant
Pandemics
Pediatrics
Pneumonia, Viral
Practice Guidelines as Topic
English While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and healthcare providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, and bronchodilators, increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic, and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.rero.ch/global/documents/182431
Statistics
Document views: 74 File downloads:
  • Full-text: 0